Notice of special administration instructions for Zemaira. Read more here X


Advanced Alpha-1 testing is the key to accurately diagnosing
an underrecognized condition.

Testing the right patients

Alpha-1 is a relatively common but underrecognized condition. According to alpha-1 antitrypsin deficiency treatment guidelines developed by the American Thoracic Society, every patient should be screened for Alpha-1 if you are treating ANY of the following2:

  • COPD, emphysema, and irreversible asthma.
  • Persistent obstruction on pulmonary function tests with known risk factors.
  • Siblings of an individual with Alpha-1.
  • Unexplained liver disease.
  • Necrotizing panniculitis.

Watch an expert discuss the importance of who to test.

Find the Alphas other test kits might miss

CSL Behring’s DNA1 Advanced Alpha-1 Screening test kit is the first and only advanced Alpha-1 detection program offering next-generation
gene sequencing.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. No clinical data are available demonstrating the effect of augmentation therapy with Zemaira or any A1-PI product on the progression of emphysema in A1-PI deficiency.

Zemaira is not indicated for lung disease patients in whom severe A1-PI deficiency has not been established.

Zemaira is contraindicated in patients with a history of severe systemic reactions to the product or to A1-PI protein, including anaphylaxis. Due to the risk of severe hypersensitivity, Zemaira is also contraindicated in immunoglobulin A-deficient patients with antibodies against IgA.

Use caution in administering Zemaira to patients who have experienced anaphylaxis or severe systemic reactions to another A1-PI product. Patients with selective or severe IgA deficiency can develop antibodies to IgA and are at greater risk of such reactions. If anaphylactic or severe anaphylactoid reactions occur during infusion, discontinue immediately.

In pre-licensure clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, asthenia, increased cough, fever, injection-site hemorrhage, rhinitis, sore throat, and vasodilation.

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Zemaira is manufactured and distributed by CSL Behring LLC.
Zemaira® is a registered trademark of CSL Behring LLC.
DNA1 Advanced Alpha-1 Screening™ is a trademark of CSL Behring LLC.

© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. ZMR03-13-0022(3) 6/2015